David L. DeRemer, Pharm.D., BCOP, FCCP

Clinical Associate Professor

PGY-2 Oncology Residency Program Director

Augusta, GA

Office: HM, Rm 106   
Voice: 706 721-4249
Fax: 706-721-3994
Twitter: http://twitter.com/DavidDeRemer


Oncology/Drug Discovery Fellowship , Univ. of Kentucky 2004-2005

Hematology/Oncology Specialty Residency (PGY2) , Univ. of Kentucky 2003-2004

Pharmacy Practice Residency (PGY1) , Univ. of Kentucky 2002-2003

Pharm.D. , Univ. of Kentucky 2002

Research Interests

Bone marrow transplant
Clinical/translational research
Hematologic malignancies
Infectious disease
Supportive care

Of Note

Board of Directors of the Hematology Oncology Pharmacy Association

Best Paper Award for Abstract  at the American College of Clinical Pharmacy (ACCP) meeting 

Won the Great Eight Research Poster competition at the ACCP Annual Meeting, in Austin, Texas

Received a Seed Grant 2014

Recertified Board Oncology Pharmacist

Board Certified Oncology Pharmacist (BCOP)

PGY2 Oncology Residency Program Director

Selected Publications

Chapters in books:
Deremer, DL. "Drug and Food Interactions with Tyrosine Kinase Inhibitors." In: Ustun Cand Popat UR (eds): Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. New york, NY: Nova Science Publishers; 2014 pp. 251-262.
Gerson SL, Bhalla KN, Grant S, Natarajan K, Creger, RJ, DeRemer DL,. Pharmacology and Molecular Mechanisms of Antineoplastics Agents for Hematologic Malignancies: Hoffman’s Hematology: Basic Principles and Practice 5th edition.

DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York. 2011 p143 -150.

DeRemer DL, Manasco KB, Fagan SC. Research: Becoming a Scholar. In: Murphy JE (ed) American College of Clinical Pharmacy Resident Survival Guide. Lenexa, KS, 2011.

Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Colorectal Cancer Chemotherapeutic Regimens 2013. McMahon Publishing, New York, NY 2013.
Journal articles:

Sisken J, DeRemer DL. Power frequency electromagnetic fields and the capacitative calcium entry system in SV40-transformed Swiss 3T3 cells. Radiation Research 2000;153:699.

Ustun C, Farrow S, DeRemer D, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplantation 2007 Jun; 39(12):807-8

Ustun C, Farrow S, El-Geneidy M, DeRemer D, Jillella A. A serious complication of allogeneic stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. Clinical Medicine:Oncology 2007: I 91-94.

Ustun C, DeRemer DL, Steele JC, et al. Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation. Int J Antimicrob Agents. 2008 Oct;32(4):365-6.

Ustun C, Kalla A, Farrow S, DeRemer DL, Jillella A. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol. 2008 Oct;83(10):825-7

DeRemer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008 Nov; 30(11):1956-75

Ustun C, DeRemer DL, Jillella AP, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. Expert Opin Investig Drugs 2009 Oct;18(10):1445-56

Adams VR, DeRemer DL, Stevich B, Mattingly C, Gallt B, Subramanian T, Troutman HM, Speilmann HP. Anticancer activity of novel unnatural synthetic isoprenoids. Anticancer Res. 2010 Jul;30(7):2505-12.

Lewis G, Hall P, Eisa N, DeRemer DL, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high dose cytarabine consolidations and thus do not require prophylaxis. Acta Haematologica 2010 Nov 12;124(4):206-213

Willis LM, Somanath PR, El-Remessy AB, DeRemer DL, Fagan SC. Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence. Clin Science 2011 Apr; 120 (8):307-19.

DeRemer DL, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of chronic myeloid leukemia. Cancer Manag and Res. 2011 Mar 10:3:65-78.

Ustun C, DeRemer DL, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis. Leukemia Res. 2011 Sep;35(9):1143-52
Bradley A, Devine M, DeRemer DL. Brentuximab vedotin: A novel antibody-drug conjugate. American Journal of Health System Pharmacists 2013 Apr 1;70(7):589-97
Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant. 2013 Apr 15 doi: 10.1038/bmt.2013.52. [Epub ahead of print]
 Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget  (in press).

Made Hodgkin Lymphoma BCOP recertification presentation at American College of Clinical Pharmacy (ACCP) Annual Meeting Albuquerque, NM. Oct. 15, 2013.
Presented Hodgkin Lymphoma BCOP recertification presentation at American Society of Health System Pharmacists annual meeting Orlando, FL. December 10, 2013.
Presented "Fosaprepitant for the Prevention of Nausea and Vomiting in Patients Receiving Beam or Hig-Dose Melphalan conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. February 2014.